Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
March 11th, 2017
7:00 AM – 8:30 AM
4441 Collins Avenue
Miami Beach, FL 33140
“Medical Crossfire®: CDK4/6 Inhibitors with the Experts: The Role of Emerging Agents for the Management of Metastatic Breast Cancer” is a live continuing medical and nursing education (CME/CE)-certified symposium to be held adjunct to the 34th Annual Miami Breast Cancer Conference®, a PER® Legacy International Conference.
Optimization of outcomes for patients with estrogen receptor‒positive (ER+), human epidermal growth factor 2‒negative (HER2-), metastatic breast cancer continues to be a significant unmet clinical need. New treatment options have emerged over the past 5 years, and the therapeutic landscape continues to evolve at a rapid pace. Clinical investigation is yielding exciting data regarding new therapies and combinations such as those involving CDK4/6 inhibitors. At the same time, the volume of information adds markedly to the complexity of the treatment decision-making process. With the potential for broader indications of CDK4/6 inhibitory therapy in breast and other tumor types, these agents are likely to become more routinely incorporated into routine use.
This interactive symposium features a panel of internationally recognized experts in breast cancer therapy who will discuss the evolving role of CDK4/6 inhibitors in the management of these patients. Faculty will address essential topics, including:
- Current perspectives on the management of patients with ER+, HER2- metastatic breast cancer
- Role of CDK4/6 in cell cycle progression regulation and tumor pathogenesis
- Rationale for pursuing CDK as a target for drug development
Development of individualized treatment algorithms that reflect an understanding of the latest clinical data pertaining to CDK4/6 inhibitors
- Recognition and management of CDK4/6 inhibitor‒related adverse events
- Tailoring treatment to specific patient populations
- Points of debate and ongoing clinical investigation
- Future indications and combination strategies for CDK4/6 inhibitors
The symposium will be held at the Fontainebleau Miami Beach on March 11 from 7:00AM–8:30AM. This is a wonderful opportunity to learn the latest and greatest state-of-the-art science around CDK4/6 inhibitory therapies in ER+, HER-, metastatic breast cancer, as well as the most up-to-date information on appropriate and optimal use of these agents.
This will be the only independent CME-certified symposium at the meeting focused entirely on CDK4/6 inhibitory approaches for metastatic breast cancer. Please join us!
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.
Upon completion of this activity, participants will be able to:
Explain the mechanism of action of CDK 4/6 inhibition in the treatment of metastatic breast cancer
- Discuss the role of current and emerging CDK4/6 inhibitory therapies in the treatment of metastatic breast cancer
- Evaluate new and emerging clinical trial data that may change standards of care for patients with metastatic breast cancer
- Identify strategies for the mitigation and management of predictable adverse events associated with emerging CDK4/6 inhibitory therapies in the management of metastatic breast cancer
- Discuss who will benefit from these agents and the importance of genetic testing
Program ChairJoyce O’Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
The US Oncology Network